T-cell

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

News

AstraZeneca’s volrustomig hits Phase 3 setback in lung cance...

In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.

R&D

pharmaphorum podcast Episode 259, Cedrik Britten, Immatics

On the power of T-cells, with Cedrik Britten

Dr Cedrik Britten, chief medical officer at Immatics, discusses novel PRAME-directed T-cell immunotherapies.

R&D

JP Morgan 2023 – Alexandre LeVert

Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs

Events

Partner Content

4th Annual Cell Engager Summit | May 24-26 | Boston, MA

Learn from the pioneers of immunotherapy

Events

Partner Content

Next Generation CAR-TCR Summit

Engineering Smarter Adoptive Cell Therapies